|
|
News Breaks | | | | January 23, 2013 | | 07:34 EDT |  | ALIM | Alimera Sciences receives final guidance from U.K.'s NICE
Alimera Sciences announced that the United Kingdom's National Institute for Health and Clinical Excellence, or NICE, has published final guidance indicating that Iluvien is not cost effective for the treatment of chronic diabetic macular edema considered insufficiently responsive to available therapies. The NICE Appraisal Committee acknowledged the clinical effectiveness of Iluvien in the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies, but noted that cost-effectiveness thresholds for the product have not yet been met. Rather than appealing the Appraisal Committee's findings, Alimera has chosen to pursue a simple PAS for Iluvien that is intended to allow treatment decisions to be based on patient need, rather than cost. | |
|
News For ALIM From The Last 14 Days Check below for free stories on ALIM the last two weeks. |
|
|
| May 14, 2013 | | 12:00 EDT |  | ALIM | Alimera Sciences rises 16.4%
Alimera Sciences is up 16.4%, or 65c, to $4.61 | |
|
|
|
|
|
|
